Roche: positive data in multiple sclerosis
(CercleFinance.com) - Roche today announced new long-term (8-year) data for Ocrevus (ocrelizumab) showing that early and continuous treatment reduced the risk of needing a walking aid by 35% after 7.
5 years for people with relapsing-remitting multiple sclerosis (RRMS), while reducing disability progression in primary progressive multiple sclerosis (PPMS) by 29% after 8 years.
The new safety data thus show a consistent benefit-risk profile in all Ocrevus clinical trials.
Three studies also showed that a shorter 2-hour infusion of Ocrevus was equally well tolerated in black, African-American, Hispanic and Latino populations compared to the overall study populations.
Roche and its research partners will also present four new abstracts on Covid-19 and vaccine response in patients treated with Ocrevus at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Copyright (c) 2021 CercleFinance.com. All rights reserved.
5 years for people with relapsing-remitting multiple sclerosis (RRMS), while reducing disability progression in primary progressive multiple sclerosis (PPMS) by 29% after 8 years.
The new safety data thus show a consistent benefit-risk profile in all Ocrevus clinical trials.
Three studies also showed that a shorter 2-hour infusion of Ocrevus was equally well tolerated in black, African-American, Hispanic and Latino populations compared to the overall study populations.
Roche and its research partners will also present four new abstracts on Covid-19 and vaccine response in patients treated with Ocrevus at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Copyright (c) 2021 CercleFinance.com. All rights reserved.